Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Affiliations

• ¹ Moffitt Cancer Center, Tampa, FL, USA. Rami.Komrokji@moffitt.org.
• ² Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
• ³ Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France.
• ⁴ Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA.
• ⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁶ Department of Haemato-Oncology, King's College London, London, UK.
• ⁷ MDS Unit, AOU Careggi, University of Florence, Florence, Italy.
• ⁸ Hematology Department, Institute of Biomedical Research of Salamanca, University Hospital of Salamanca, Salamanca, Spain.
• ⁹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", Bologna, Italy.
• ¹⁰ Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
• ¹¹ Stanford University Cancer Center, Stanford, CA, USA.
• ¹² Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL, USA.
• ¹³ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
• ¹⁴ Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
• ¹⁵ Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.
• ¹⁶ Bristol Myers Squibb, Princeton, NJ, USA.
• ¹⁷ Acceleron Pharma, Cambridge, MA, USA.
• ¹⁸ Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA.